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Abstract
Mutually exclusive genetic alterations in the RET, RAS, or BRAF genes, which result in constitutively active mitogen-
activated protein kinase (MAPK) signaling, are present in about 70% of papillary thyroid carcinomas (PTCs). However,
the effect of MAPK activation on other signaling pathways involved in oncogenic transformation, such as Notch,
remains unclear. In this study, we tested the hypothesis that the MAPK pathway regulates Notch signaling and that
Notch signaling plays a role in PTC cell proliferation. Conditional induction of MAPK signaling oncogenes RET/PTC3 or
BRAFT1799A in normal rat thyroid cell line mediated activation of Notch signaling, upregulating Notch1 receptor and
Hes1, the downstream effector of Notch pathway. Conversely, pharmacological inhibition of MAPK reduced Notch
signaling in PTC cell. Thyroid tumor samples from transgenic mice expressing BRAFT1799A and primary human PTC
samples showed high levels of Notch1 expression. Down-regulation of Notch signaling by γ-secretase inhibitor (GSI)
or NOTCH1 RNA interference reduces PTC cell proliferation. Moreover, the combination of GSI with a MAPK inhibitor
enhanced the growth suppression in PTC cells. This study revealed that RET/PTC and BRAFT1799A activate Notch
signaling and promote tumor growth in thyroid follicular cell. Taken together, these data suggest that Notch signaling
may be explored as an adjuvant therapy for thyroid papillary cancer.
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Introduction
Thyroid cancer is the most common endocrine malignancy and its
incidence continues to increase [1]. Papillary thyroid carcinoma (PTC)
is the most prevalent type of thyroid cancer accounting for 80% of cases
[1–3]. In PTC, genetic alterations in mitogen-activated protein kinase
(MAPK) signaling components such as RET/PTC, RAS, and BRAF
are well studied and result in constitutive activation of the MAPK sig-
naling pathway [4–7]. The RET/PTC and BRAFT1799A oncogenes are
involved in thyroid tumorigenesis as demonstrated by targeted expression
of RET/PTC or BRAFT1799A oncogenes in transgenic mice, suggesting
that mutations in MAPK signaling components contribute for trans-
formation to PTC [8,9]. However, the mechanism of concomitant acti-
vation of different signaling pathways by these oncogenes in thyroid
cancer is not fully understood.
Notch signaling is critical for the development and maintenance
of tissue homeostasis [10]. The Notch signaling pathway comprises
a family of transmembrane receptors and their ligands; to date, four
mammalian receptors (Notch1, 2, 3, and 4) and at least five ligands
[Delta 1, 3, and 4 and Jagged (Jag) 1 and 2] have been identified. Bind-
ing of the ligand renders the Notch receptor susceptible to sequential
proteolytic cleavage mediated by ADAMmetalloprotease and γ-secretase
enzymes, which in turn results in the release of the Notch intracellular
domain from the plasma membrane and its subsequent translocation
into the nucleus [10,11]. Notch intracellular domains function within
the nucleus as co-activators with the CBF1/RBPjκ in mammalian,
Suppressor of Hairless Su(H) in Drosophila melanogaster, Lag1 in
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Caenorhabditis elegans family of transcription factors to promote tran-
scription of target genes such as hairy and enhancer of split 1 (HES1) and
hair/enhancer of split related with YRPW motif [12]. Aberrant Notch
signaling has been linked to a wide variety of tumor types and can
either suppress or promote tumorigenesis depending on the cell type
and context. Activated Notch has been shown to transform primary
Schwann cells [13], melanocytes [14], and epithelial breast cells [15].
Notch signaling dysregulation has been observed in small cell lung can-
cer, neuroblastoma, and breast, cervical, and prostate carcinoma [16–
20]. In PTC, a large-scale gene expression analysis showed enhanced
gene expression of several components of Notch signaling [21].
Growing evidence indicates that MAPK signaling pathway impacts
Notch signaling. For instance, the expression of mutated RasV12 up-
regulates Notch1 protein expression in fibroblast and epithelial human
cell lines, which suggests Notch as a key downstream target of onco-
genic RAS [22]. Since activation of MAPK signaling is the most fre-
quent oncogenic genetic alteration in PTC, we hypothesized that the
two most critical oncogenes implicated in PTC tumorigenesis, RET/
PTC and BRAFT1799A, regulate Notch signaling and that the Notch
pathway is involved in PTC proliferation.
Materials and Methods
Cell Culture, Transfection, and Tumor Samples
The rat thyroid cell line (PCCL3) conditionally expressing either
the RET/PTC3 or BRAFT1799A oncogenes, designed PTC3-5 [23]
and PC-BRAF [24] cells, respectively, were maintained in Ham’s F12
medium supplemented with 5% FBS, 1 mIU/ml bovine thyroid–
stimulating hormone (Sigma, St Louis,MO), 10 μg/ml insulin (Sigma),
5 μg/ml apotransferrin (Sigma), 10 nMhydrocortisone (Sigma), 100U/ml
penicillin (Invitrogen Life Technologies, Carlsbad, CA), 100 μg/ml
streptomycin (Invitrogen Life Technologies), and 1 μg/ml amphotericin
B (Invitrogen Life Technologies). Doxycycline (Calbiochem, SanDiego,
CA) was used to induceRET/PTC3 andBRAFT1799A oncogenes.Human
PTC cell lines (TPC-1 and BCPAP) were maintained in Dulbecco’s
modified Eagle’s medium with 100 U/ml penicillin, 100 μg/ml strep-
tomycin, and 1 μg/ml amphotericin. Media for TPC-1 cells were
supplemented with 5% FBS, while media for BCPAP cells were sup-
plemented with 10% FBS. PD98059 and U0126 (Promega, Madison,
WI) were used to inhibitmitogen-activated or extracellular signal-related
protein kinase kinase (MEK) activity, and Z-Leu-Leu-Nle-CHO
was used to inhibit-secretase activity (Calbiochem). TPC-1 cell line
was transiently transfected with 10 or 30 nM of siRNA-NOTCH1 or
siRNA-enhanced green fluorescent protein (EGFP) (esiRNA human
NOTCH1-EHU150431; esiRNA targeting EGFP-EHUGFP; Sigma)
using Lipofectamine 2000, according to the manufacturer’s instructions
(InvitrogenLife Technologies). Plasmid pBABE-NOTCH1 and pBABE
empty vector were transfected in PCCL3 cell line to generate the PC-
NOTCH1 and PC-Ø, respectively, and selected with neomycin (300 μg/ml).
PC-BRAF cells (1 × 104/well) were seeded into 24-well plates and
co-transfected in triplicate with 300 ng of 4× CBF1-Luc and 30 ng
of pRL-CMV using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s protocol. One day after transfection, cells were
treated with 1 μg/ml doxycycline, and 72 hours after oncogene induc-
tion, luciferase activity was measured using the Luciferase Reporter
Assay System (Promega) according to the manufacturer’s instructions.
Human PTC and nontumor paired thyroid tissue samples were col-
lected from patients with informed consent. This study complied with
the guidelines from the ethical committee of the Institute of Biomedical
Sciences (No. 193/F93/L02), University of Sao Paulo.
Cell Proliferation Assays
Human PTC cells, PC-Ø, and PC-NOTCH1 were seeded into
six-well plates at a density of 1 × 104 cells/well. TPC-1 was transfected
with siRNA-NOTCH1 (30 nM) or siRNA-EGFP (30 nM). Cells were
enumerated using a flow cytometry–based cell counter, the Guava
EasyCyte (Guava Technology, Billerica, MA). The average cell number
at each time point was obtained from triplicate measurements. To
assess cell viability using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) assay, human PTC cells were seeded into
96-well plates at a density of 5 × 103 cells/well. MTT (Amresco, Solon,
OH) was added to the medium at a concentration of 0.125 mg/ml and
cells were solubilized in 100 μl of 0.04 M HCl in isopropanol; absor-
bance at 595 nm was measured using a spectrophotometer (Spectra
Max Plus; Molecular Devices, Sunnyvale, CA).
Flow Cytometry
PTC cells were collected by trypsinization and double stained with
fluorescein isothiocyanate (FITC)–conjugated annexin V and propidium
iodide for 15 minutes at room temperature according to the manufac-
turer’s instructions (Annexin V FITC Kit; Invitrogen Life Technologies)
followed by analysis with a flow cytometer (Guava Technology).
Quantitative Polymerase Chain Reaction
Total RNA was extracted by phenol-chloroform method using the
TRIzol reagent (Invitrogen Life Technologies). The first strand of
cDNA was generated from 1 μg of total RNA in the presence of Oligo
dT and MMLV reverse transcriptase (Invitrogen Life Technologies).
Polymerase chain reaction (PCR) amplification was performed in
duplicate using SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA) in an ABI 7300 Real-Time PCR System (Applied
Biosystems) using primers as shown in Table W1. Gene expression
was normalized to the RPL19 gene. Data were calculated using the
2-ΔΔCT method [25] and are presented as the fold change in gene
expression relative to the control sample.
Western Blot Analysis
Total protein lysates were extracted using RIPA buffer [20 mM Tris
(pH 7.5), 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxy-
cholate, 1 mM EDTA, and 0.1% sodium dodecyl sulfate (SDS)] con-
taining protease inhibitor cocktail (Sigma). Protein concentration was
measured using the Bradford method (Bio-Rad Laboratories, Hercules,
CA) and 15 to 30 μg of each sample was separated by 10% to 12%
SDS–polyacrylamide gel electrophoresis (PAGE) and blotted onto
a nitrocellulose membrane (Hybond-ECL; Amersham Biosciences,
Little Chalfont, United Kingdom). Nonspecific binding sites were
blocked by incubating with 5% nonfat dry milk in Tris-buffered
saline–0.1% Tween-20. The following primary antibodies were used:
anti-ERK1 (K23), anti–phospho-extracellular signal-regulated kinase
(ERK) (Tyr 204) (E4), anti-Notch1 (C20), anti–α-tubulin (B-7), anti–
cyclinD1 (H-295) (all from Santa Cruz Biotechnology, Santa Cruz, CA),
and anti–α-actin (A2066) (Sigma). The antigen-antibody complexes
were visualized using an HRP-conjugated secondary antibody and an
enhanced chemiluminescence system (Amersham Biosciences).
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Figure 1. RET/PTC3 and BRAFT1799A inducible system activates MAPK signaling pathway and increases Notch1 mRNA and protein ex-
pression. (A) PTC3-5 and PC-BRAF doxycycline-inducible cells were treated with the indicated concentration of doxycycline for 72 hours
and real-time PCRwas performed to determineNotch1 gene expression levels. mRNA levels are expressed as the fold change relative to the
control group. (B) PTC3-5 and PC-BRAF cells were treated with the indicated concentration of doxycycline for 72 hours and Western blot
of total protein lysates was carried out for Notch1 (115 kDa), phospho-ERK (pERK, 42 and 44 kDa), total ERK (42 and 44 kDa), and α-actin
(42 kDa). (C) PTC3-5 and PC-BRAF doxycycline-inducible cells were treated with 1 μg/ml doxycycline for the indicated time periods and
real-time PCR was performed to determine Notch1 gene expression levels. mRNA levels were expressed as the fold change relative to
the control group. (D) PTC3-5 and PC-BRAF doxycycline-inducible cells were treated as indicated in C and Western blot of total protein
lysates was performed. (E) CBF1 activity was measured in PC-BRAF cell transfected with the 4× CBF-Luc reporter plasmid containing four
CBF1-responsive elements. Luciferase activity was measured 72 hours after BRAFT1799A oncogene induction with 1 μg/ml doxycycline.
(F) PTC3-5 and PC-BRAF doxycycline-inducible cells were treated as indicated in C and real-time PCR was performed to determine Hes1
and Jag1 gene expression levels. mRNA levels were expressed as the fold change relative to the control group. Data are expressed as the
means ± SE (n = 3). *P < .05 versus control; **P < .01 versus control; ***P < .001 versus control.
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Immunohistochemistry and Immunofluorescence
Immunohistochemistry to detected Notch1 protein expression was
performed on formalin-fixed paraffin-embedded tissue sections by an
indirect three-stage immunoenzymatic method as previously described
[26]. Immunodetection of Notch1 protein (1:100, C-20; Santa Cruz
Biotechnology) expression was performed on 3-μm sections and the
presence of brown immunoprecipitates visible under a light microscope
(Eclipse E600;Nikon, Tokyo, Japan) indicated positive immunostaining.
Immunofluorescence was performed as previously described [27]. In brief,
coverslip cell cultures were fixed in 3.7%paraformaldehyde, permeabilized,
and blocked with 1% BSA. Cell slides were incubated with anti-Notch1
antibody (1:200, C-20; Santa Cruz Biotechnology) and anti–α-tubulin
(1:500, B-7; Santa Cruz Biotechnology), then with Alexa Fluor 488–-
conjugated anti-rabbit and Alexa Fluor 532 anti-mouse IgG secondary
antibodies (Invitrogen). The nuclei was detected with 4′,6-diamidino-
2-phenylindole (1 μg/ml; Sigma). Coverslip cultures were mounted in
inverted positions on glass slides and analyzed in confocal and multi-
photon microscope (LSM 780; Carl Zeiss, Jena, Germany).
Statistical Analysis
The data were expressed as means ± SE. The Student’s t test was
used to compare control and treated groups, and when appropriate, a
one-way analysis of variance followed by Tukey tests was used for mul-
tiple comparisons. P < .05 was used to indicate statistical significance.
The statistical analysis was performed using the software package,
GraphPad Prism (Prism 5.01; GraphPad Software, La Jolla, CA).
Results
Notch Signaling Is Upregulated after MAPK Activation
We asked whether activation of MAPK signaling could regulate
the Notch pathway and we used a system with conditional activation
of the RET/PTC3 or BRAFT1799A oncogenes by doxycycline in a nor-
mal rat thyroid cell line (PCCL3), designated PTC3-5 and PC-BRAF,
respectively. The induction of RET/PTC3 or BRAFT1799A oncogenes
by doxycycline was confirmed by Western blot as we observed a dose-
dependent increase in ERK phosphorylation (pERK), a downstream
component of MAPK signaling. Notch1 mRNA and protein levels
were increased after RET/PTC3 or BRAFT1799A activation (Figure 1,
A and B). The time course analysis revealed that Notch1 mRNA levels
increased after 24 hours, with extended up-regulation 72 hours after
oncogene induction in the PTC3-5 cell line (Figure 1C ). During
BRAFT1799A activation, up-regulation of Notch1 mRNA levels was also
observed at 24 and 48 hours post-treatment. Higher Notch1 protein
expression was showed after oncogene activation in PTC3-5 and
PC-BRAF cell lines (Figure 1D). In addition, BRAFT1799A oncogene
induction activates CBF1 luciferase reporter, suggesting the canonical
activation of Notch signaling by MAPK pathway (Figure 1E ). In
PTC3-5 and PC-BRAF cell lines, oncogene activation increased
HES1 mRNA levels (a downstream target gene of Notch signaling)
after 48 and 72 hours, respectively, confirming the activation of Notch
signaling by the RET/PTC3 and BRAFT1799A oncogenes (Figure 1F).
Moreover, gene expression of the Notch signaling ligand, Jag1, was
also upregulated after the activation of both oncogenes (Figure 1F ),
suggesting a potential mechanism for the up-regulation of Notch
signaling by the MAPK pathway. To assess the influence of Notch
signaling in a normal follicular thyroid cell proliferation, we used
isogenic cell lines with ectopic expression of Notch1 intracellular
domain (PC-NOTCH1). The growth curve analysis showed nomodu-
lation in PC-NOTCH1 cell growth (Figure W1).
To test whether Notch1 is modulated in vivo, we used transgenic
mice Tg-BRAF, which harbor the BRAFT1799A oncogene under the
control of the thyroglobulin promoter, driving the oncogene activation
only in thyroid tissue [28]. Immunohistochemistry analysis of Notch1
protein expression in thyroid glands obtained from wild-type animals
Figure 2. Notch1 expression is upregulated in a PTC mouse model and in human PTC samples. (A) Representative photomicrographs
of immunostaining for Notch1 in wild-type and Tg-BRAF mouse thyroid gland tissue sections. Notch1 staining is shown in brown, and
Gill’s hematoxylin was used as a counterstain. The inset depicts the negative control. (B) NOTCH1 mRNA levels from human PTC and
nontumor paired thyroid tissue samples were analyzed using real-time PCR. (C) NOTCH1 protein expression was analyzed by Western
blot using antibodies against NOTCH1 (115 kDa) and α-actin (42 kDa) in human PTC and nontumor. N, nontumor sample.
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showed normal thyroid tissue architecture, with positive and negative
staining for Notch1 in cells within the same follicle. In contrast,
Tg-BRAF mice showed disrupted thyroid architecture, no evident
colloid material, and strong positive staining for Notch1 in follicular
and stromal cells (Figure 2A). In human PTC samples, 64% (9/14)
showed elevated levels ofNOTCH1 gene expression (Figure 2B).When
NOTCH1 protein expression was analyzed by Western blot, non-
tumor paired thyroid samples exhibited heterogeneous levels. However,
PTC samples exhibited high levels of NOTCH1 protein expression
when compared with nontumor samples (Figure 2C).
Figure 3. Inhibition of the MAPK pathway decreases NOTCH1 and HES1 gene expression in TPC-1 cell line. TPC-1 and BCPAP cell lines
were treated with the MEK inhibitors PD98059 (20 μM) and U0126 (10 μM), and BCPAP cell line was treated with PLX4032 (1 μM). After
48 hours (PD98059 and U0126 treatment) and 24 hours (PLX4032), real-time PCR was performed to determine NOTCH1 and HES1 gene
expression levels. mRNA levels are expressed as the fold change relative to the control. Data are expressed as the means ± SE (n = 3).
**P < .01 versus control; ***P < .001 versus control.
Figure 4. NOTCH1 gene silence regulates PTC cell proliferation. (A) TPC-1 cell line was transfected with siRNA targeting NOTCH1 (siN1) or
siRNA targeting EGFP (siEGFP) with the indicated concentration, and 48 hours after transfection, total protein lysates were separated by
SDS-PAGE and analyzed by Western blot for NOTCH1 (115 kDa) and α-tubulin (52 kDa). (B) TPC-1 cells were plated in six-well plates and
transfected with siRNA targeting NOTCH1 (siN1; 30 nM) or siRNA targeting EGFP (siEGFP; 30 nM); the number of cells was determined
over time. Data are expressed as the means ± SE (n = 3). (C) TPC-1 cell lines transfected with siRNA targeting NOTCH1 (siN1; 30 nM) or
siRNA targeting EGFP (siEGFP; 30 nM), and after 96 hours, annexin V/propidium iodide staining followed by flow cytometry analysis was
performed to quantify apoptosis (phosphatidylserine externalization). Data are expressed as the means ± SE (n = 3). *P < .05.
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Suppression of MAPK Signaling Pathway Decreases
Notch Signaling
To establish whether Notch signaling activation in thyroid tumors
is dependent on the MAPK pathway, the TPC-1 and BCPAP,
human PTC cell lines harboring RET/PTC1 and BRAFT1799A, re-
spectively, were treated with MEK inhibitors and NOTCH1 and
HES1 mRNA levels were examined. BCPAP cell line was also treated
with PLX4032, a specific inhibitor of mutated BRAFV600E. MAPK
pathway inhibition was confirmed by markedly decreased pERK
levels (Figure W2). NOTCH1 and HES1mRNA levels were decreased
after 48 hours of MAPK inhibition in the TPC-1 cell line (Figure 3).
However, no significant changes in NOTCH1 or HES1 mRNA levels
were observed after MAPK signaling inhibition in the BCPAP cell
line (Figure 3).
Notch Signaling Inhibition Reduces Proliferation of
PTC Cell Lines
To assess the influence of Notch signaling in the proliferation of
PTC cell lines, we used small-interfering RNA against NOTCH1. A
reduction of NOTCH1 protein levels by 76% and 52% was ob-
served after 24 and 48 hours of siRNA transfection (30 nM), respec-
tively (Figure 4A). Silencing of NOTCH1 decreased cell proliferation
and augmented apoptosis in TPC-1 cell line (Figure 4, B and C ). We
then used γ-secretase inhibitor (GSI) to pharmacologically deplete
Notch signaling in TPC-1 and BCPAP cells. Immunofluorescence
of Notch1 and gene expression analysis of the Notch target gene
HES1 confirm the inhibition of Notch signaling by GSI, observed
by NOTCH1 full-length accumulation at the cell membrane in
TPC-1 cells (Figure 5A) and by a reduction in HES1 mRNA levels
Figure 5. GSI regulates PTC cell proliferation. (A) Double staining for Notch (green) and α-tubulin cytoskeleton expression (red) was
performed in TPC-1 cells 24 hours after GSI (1 μM) treatment. Nucleus were stained with 4′,6-diamidino-2-phenylindole (blue). Scale bar,
50 μm. Arrows indicates NOTCH1 receptor accumulation in cell membrane. (B) TPC-1 and BCPAP cell lines were treated with GSI (1 μM) or
vehicle solution (DMSO). After 48 hours, real-time PCR was performed to determine HES1 gene expression. mRNA levels were expressed
as the fold change relative to the control group. Data are expressed as the means ± SE (n= 3). (C) TPC-1 and BCPAP cell lines were treated
with the indicated concentration of GSI or vehicle solution (DMSO). After 48 hours, the percentage of viable cells was determined by MTT
assay. (D) TPC-1 and BCPAP cells were plated in six-well plates and treated with GSI (1 μM) or vehicle solution (DMSO); the number of
cells was determined over time. *P < .05 versus control; **P < .01 versus control; ***P < .001 versus control.
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(Figure 5B). We observed a dose-dependent reduction of cell viability
in PTC cell lines after treatment with GSI for 48 hours (Figure 5C ).
In addition, the treatment of PTC cell lines with GSI significantly
decreased the cellular proliferation rate of both cell lines when com-
pared to untreated cells (Figure 5D).
Pharmacological inhibition of Notch signaling modulates cell cycle–
related genes in the TPC-1 cell line, increasing the mRNA levels of the
cell cycle arrest–related genes CDKN1A and CDKN1B and decreasing
the cell cycle progression–related genes CCND1, MCM6, CKS2, and
MAD2L. Similar results were observed in the BCPAP cell line, except
that significantly decreased CDKN1A mRNA levels were observed
(Figure 6A). To determine the percentage of apoptotic cells, we treated
PTC cell lines with GSI for 24 and 48 hours and double stained with
FITC-conjugated annexin V and propidium iodide. Treatment of
PTC cells with GSI increased apoptosis in a time-dependent manner
(Figure 6B).
Inhibition of Notch Signaling Enhances the Growth
Suppression Promoted by MEK Inhibitors in PTC Cells
Since it is well established that MAPK suppression regulates PTC
cell growth, we assessed whether Notch signaling would be important
for MAPK-mediated cell proliferation. Thus, we tested the influence
Figure 6. GSI regulates cell cycle–related genes and induces apoptosis in PTC cells. (A) TPC-1 and BCPAP cells were treatedwith GSI (1 μM)
or vehicle solution (DMSO), and after 48 hours of treatment, real-time PCR was performed to quantify CCND1, CDKN1A, CDKN1B,MCM6,
CKS2, andMAD2L gene expression. mRNA levels are expressed as the fold change relative to the control group. Data are expressed as the
means ± SE (n = 3). (B) Annexin V/propidium iodide double staining followed by flow cytometry analysis was performed to quantify apop-
tosis (phosphatidylserine externalization) in TPC-1 and BCPAP cell lines treated with GSI (1 μM) or vehicle solution (DMSO) for the indicated
time periods. Data are expressed as the means ± SE (n= 3). *P < .05 versus control; **P< .01 versus control; ***P < .001 versus control.
Figure 7. GSI treatment enhances the growth suppression pro-
moted by MAPK signaling in PTC cells. TPC-1 and BCPAP cell lines
were treated with GSI (0.1 μm) and MEK inhibitor PD98059 (20 μM)
or U0126 (10 μM), and after 48 hours, a cell viability assay was per-
formed. Data are expressed as the means ± SE (n = 3). *P < .05
versus control; ***P < .001 versus control; #P < .01 versus U0126.
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of low-dose GSI treatment on the growth suppression induced by
MAPK inhibition. As expected, after 48 hours an anti-proliferative
effect was observed in PTC cells following the treatment with MEK
inhibitors, with an especially marked response in BCPAP cells (Figure 7).
The inhibition of Notch signaling by GSI produced no cumulative effect
on cell viability when cells were concurrently treated with the PD98056
MEK1-specific inhibitor. However, the addition of GSI slightly
enhanced the growth suppression induced by the MEK1/2 inhibitor
U0126 in both PTC cell lines (Figure 7). These data indicate that
the concomitant inhibition of Notch and MAPK signaling produce a
cumulative effect on cell proliferation. No further effects were observed
using higher concentrations of GSI (1 μM) along with the MEK inhibi-
tors in either PTC cell line (data not shown).
Discussion
Notch signaling has been implicated in the pathogenesis of different
types of cancer [20]. Here, we demonstrate that Notch signaling is con-
trolled by the MAPK pathway oncogenes, RET/PTC and BRAFT1799A,
which are associated with thyroid cancer, and that inhibition of Notch
signaling results in antiproliferative effect in PTC cells. Although Notch
signaling has been shown to suppress tumor growth in cancer-derived
keratinocytes, several lines of evidence indicate that it can play an
oncogenic role in neurologic, hematological, and epithelial cancers,
suggesting that overall result of Notch signaling is cell type dependent
[19]. Up-regulation of NOTCH1 protein expression has been observed
in pancreas and breast cancer [15,29]. In thyroid cancer, NOTCH1
expression differs among tumor histologic classification. In human
anaplastic thyroid carcinoma, NOTCH1 gene expression is down-
regulated [30]. By contrast, human PTCs, including microcarcinomas,
classic and follicular variants, show higher expression of NOTCH1
when compared with normal thyroid tissues and peritumoral regions
[31]. In addition, microarray analysis also indicates that several com-
ponents of the Notch signaling pathway are upregulated in human
PTC [21]. Corroborating these data, we observed an up-regulation of
NOTCH1 expression in PTC samples derived from human and trans-
genic animals. Together, these data suggest that the Notch signaling
pathway is dysregulated in PTC.
Genetic alterations in MAPK signaling oncogenes are implicated in
the initial steps of PTC tumorigenesis [8,9,28]. By analyzing the influ-
ence of RET/PTC3 or BRAFT1799A in Notch signaling regulation, we
demonstrated that both oncogenes implicated in thyroid tumorigenesis
are involved in the up-regulation of Notch signaling. In nontumor
thyroid cell lines, the MAPK pathway and Notch signaling cooperate
to promote neoplasia. For instance, the MAPK pathway has been
shown to regulate Jag1/Notch signaling and induces tumor angio-
genesis in a head and neck squamous cell line [32] and tumorigenesis
in pancreatic and lung cancer [29,33]. Although both RET/PTC and
BRAF oncogenes can activate MAPK signaling, PTC oncogenes can
elicit alternative pathways as well. RET/PTC and BRAFT1799Amodulate
different signaling pathways in PTC [34,35]. For instance, RET/PTC
oncogene activates the β-catenin signaling pathway [36] and down-
regulates let-7 microRNA [24], while BRAFT1799A induces nuclear factor-
kappa B (NF-κB) signaling [37] and extracellular matrix remodeling
[34]. Interestingly, blocking MAPK signaling through MEK inhibi-
tors differentially regulates Notch signaling in PTC cell lines, TPC-1
(harboring RET/PTC1 rearrangement) and BCPAP (harboring
BRAFT1799A mutation), indicating that different steps in the MAPK
cascade control Notch expression.
Considerable attention has been focused on proliferative effects re-
sulting from Notch signaling. In our model, we observed that Notch
signaling inhibition regulates cell cycle regulatory genes that are tightly
linked to cell cycle phase transition in PTC cells. In fact, Notch sig-
naling directly regulates genes involved in cell cycle progression such
as c-MYC [38],MCM2, MCM6 [39], and CCND1 [40] and cell cycle
inhibition such as CDKN1A [41] and CDKN1B [42]. Moreover, we
observed that inhibition of Notch signaling increased apoptosis in
PTC cell lines. NOTCH1 gene silencing also decreased TPC-1 cell
proliferation as observed in other epithelial cancer types, indicating
the influence of NOTCH1 in cell proliferation [15,19].
Here, we show that genetic alterations in RET/PTC and BRAFT1799A
in PTC lead to the activation of Notch signaling and contribute to
tumor growth. Since Notch signaling components participates in
tumor growth and are associated with poor prognosis in several types
of cancer, including PTC, targeting Notch signaling could be a promis-
ing therapeutic approach to cancer treatment [43–46]. In conclusion,
this work establishes a link between MAPK and Notch signaling
pathways that control tumor growth in PTC. These data suggest that
targeting Notch signaling may offer a potential adjuvant therapy for
Notch-expressing PTC.
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Table W1. Primers Used for Real-Time PCR.
Gene (Species) Sequence (5′→3′)
NOTCH1 (Homo sapiens) Fw: GGCTAACAAAGATATGCAGAACAACA
Rev: GTCCCGGTTGGCAAAGTG
HES1 (Homo sapiens) Fw: AGGCGGACATTCTGGAAATG
Rev: AGCGCAGCCGTCATCTG
CCND1 (Homo sapiens) Fw: CTGTGCATCTACACCGACAACTC
Rev: CCAGGTTCCACTTGAGCTTGTT
CDKN1A (Homo sapiens) Fw: CTGGAGACTCTCAGGGTCGAA
Rev: GGCGTTTGGAGTGGTAGAAATCT
CDKN1B (Homo sapiens) Fw: AGACGGGGTTAGCGGAGCAA
Rev: TCTTGGGCGTCTGCTCCACA
CKS2 (Homo sapiens) Fw: GGCCCACAAGCAGATCTACTACTC
Rev: GGGTAACATAACATGCCGGTACTC
MCM6 (Homo sapiens) Fw: TGCCTGACGTCTCCAAGCTTA
Rev: CACTGACACGGGAATTAGTTTCTG
MAD2L (Homo sapiens) Fw: CGTGGCCGAGTTCTTCTCA
Rev: AGATGGATATATGCCACGCTGAT
RPL19 (Homo sapiens) Fw: TCTCATGGAACACATCCACAA
Rev: TGGTCAGCCAGGAGCTTCTT
Notch1 (Rattus Norvegicus) Fw: AGCCAACAAAGACATGCAGAAC
Rev: GTCCCGGTTGGCAAAGTG
Hes1 (Rattus Norvegicus) Fw: GAAAACACTGATTTTGGATGCACTT
Rev: CGCGGTACTTCCCCAACAC
Rpl19 (Rattus Norvegicus) Fw: GGCCCGCAAGAAGCTACTG
Rev: TTCGTGCTTCCTTGGTCTTAGA
Figure W1. Notch1 intracellular domain does not modulate proliferation in normal follicular thyroid PCCL3 cell line. (A) Total protein lysates
from PC-Φ and PC-NOTCH1 were separated by SDS-PAGE and analyzed by Western blot for NOTCH1, and α-tubulin was used as a loading
control. (B) Total RNAwas extracted and used for cDNA synthesis, and real-time PCRwas performed to determineNOTCH1 andHES1 gene
expression levels. mRNA levels are expressed as the fold change relative to the control. (C) PC-Φ and PC-NOTCH1 cell numbers were de-
termined over time. Data are expressed as the means ± SE (n = 3).
Figure W2. Validation of MAPK signaling disruption by BRAF and MEK inhibitors in PTC cells. TPC-1 and BCPAP cell lines were treated
with the MEK inhibitors PD98059 (20 μM) and U0126 (10 μM), and the BCPAP cell line was treated with PLX4032 (1 μM). Fourth-
eight hours (PD98059 and U0126) and 24 hours (PLX4032) after the treatment, total protein lysates were separated by SDS-PAGE
and analyzed by Western blot for pERK (42 and 44 kDa) and total ERK (42 and 44 kDa). α-Actin (42 kDa) or α-tubulin (55 kDa) was used
as a loading control.
